Idarubicin
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-IDARUBICIN |
|---|---|
| Type | Drug |
| Aliases | IdamycinZavedosІдарубіцин |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-APL |
| Sources | SRC-ELN-APL-2019 SRC-NCCN-AML-2025 |
Drug Facts
| Class | Anthracycline (topoisomerase II inhibitor + DNA intercalator) |
|---|---|
| Mechanism | Lipophilic anthracycline analog of daunorubicin; better intracellular penetration. Same mechanism as daunorubicin but somewhat lower cardiotoxicity per dose. Used as alternative anthracycline in AML 7+3 and as anthracycline component of high-risk APL induction (AIDA / AIDA-like schemes). |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Warnings
- Cardiotoxicity (cumulative)
- Severe myelosuppression
- Vesicant — extravasation causes severe tissue necrosis
Notes
Interchangeable with daunorubicin in 7+3 (no clear OS difference in meta-analysis). Anthracycline of choice in classic AIDA APL induction. Cumulative lifetime threshold lower than daunorubicin (~150 mg/m²).
Used By
Regimens
REG-ATRA-ATO-IDA-APL- ATRA + ATO + Idarubicin (APL high-risk) — modified APL0406 / AIDA-style